enGene Holdings Inc. Warrants carries a market capitalization of 8.70M, placing it among publicly traded companies globally. Its enterprise value stands at -213.63M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 8.70M |
| Enterprise Value | -213.63M |
enGene Holdings Inc. Warrants currently has 67.01M shares outstanding.
| Shares Outstanding | 67.01M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.08 |
| P/TBV Ratio | 0.08 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
enGene Holdings Inc. Warrants maintains a current ratio of 10.21, meaning it holds 10.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.45, indicating elevated leverage, while an interest coverage ratio of -44.28 demonstrates limited ability to service its debt obligations.
| Current Ratio | 10.21 |
| Quick Ratio | 9.82 |
| Debt / Equity | 14.45 |
| Debt / EBITDA | -0.24 |
| Interest Coverage | -44.28 |
| Return on Equity (ROE) | -60.50 |
| Return on Assets (ROA) | -48.84 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
| Income Tax | -497,000.00 |
| Effective Tax Rate | N/A |
enGene Holdings Inc. Warrants's stock has declined approximately -93.6367% over the past 52 weeks. The 50-day moving average sits at 0.43, while the 200-day moving average is 1.78.
| Beta (5Y) | N/A |
| 52-Week Price Change | -93.6367% |
| 50-Day Moving Average | 0.43 |
| 200-Day Moving Average | 1.78 |
| Average Volume (20 Days) | N/A |
EBITDA reached -135.93M, while operating income came in at -136.65M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -136.65M |
| Pretax Income | -130.86M |
| Net Income | -130.36M |
| EBITDA | -135.93M |
| EBIT | -136.65M |
| Earnings Per Share (EPS) | N/A |
enGene Holdings Inc. Warrants holds 266.32M in cash and equivalents against 33.27M in total debt, resulting in a net debt position of -15.67M. Total book value stands at 230.29M, with working capital of 250.69M providing operational flexibility.
| Cash & Cash Equivalents | 266.32M |
| Total Debt | 33.27M |
| Net Debt | -15.67M |
| Equity (Book Value) | 230.29M |
| Book Value Per Share | 3.44 |
| Working Capital | 250.69M |
enGene Holdings Inc. Warrants produced -103.31M in operating cash flow over the past twelve months.
| Operating Cash Flow | -103.31M |
| Capital Expenditures | -688,000.00 |
| Free Cash Flow | -104.00M |
| FCF Per Share | N/A |
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -740.18 |
| FCF Yield | N/A |
enGene Holdings Inc. Warrants posts an Altman Z-Score of -2.58, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.58 |
Already premium? Sign in